Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Published 27 May 2009, doi:10.1136/bmj.b1684
Cite this as: BMJ 2009;338:b1684
Roberta Richey, technical analyst1, Peter Howdle, professor of clinical medicine2, Elizabeth Shaw, technical adviser1, Tim Stokes, associate director1, on behalf of the Guideline Development Group
1 Centre for Clinical Practice (Short Clinical Guidelines), National Institute for Health and Clinical Excellence, Manchester M1 4BD, 2 Leeds Institute of Molecular Medicine, St Jamess University Hospital, Leeds LS9 7TF
Correspondence to: P Howdle p.d.howdle@leeds.ac.uk
| The first 150 words of the full text of this article appear below. |
Coeliac disease is an autoimmune condition that can be diagnosed at any age. Although it has been traditionally associated with mainly gastrointestinal signs and symptoms, its non-gastrointestinal features have been increasingly recognised.
Given its varied clinical manifestations and the historical belief that it is relatively uncommon,1 2 concern has been raised that coeliac disease—and its possible long term consequences—is being underdiagnosed. It has also been shown to be more prevalent in people with other autoimmune conditions.3 This article summarises the most recent recommendations from the National Institute for Health and Clinical Excellence (NICE) on the recognition and assessment of coeliac disease.4
NICE recommendations are based on systematic reviews of best available evidence. When minimal evidence is available, recommendations are based on the Guideline Development Groups experience and opinion of what constitutes good practice. Evidence levels for the recommendations are given in italic in square brackets.
Read all Rapid Responses